###### What is already known on this topic

-   Extended recording of pulse oximetry can provide important information about the health of an individual relatively non-invasively in a hospital environment.

-   SpO~2~ reference data, stratified by sleep-state in term infants aged 2 weeks--24 months, are currently not available for modern high temporal resolution pulse-oximeters.

-   Summary statistics, such as mean and medians, do not capture the overall distribution of extended SpO~2~ recordings.

###### What this study adds

-   This study provides reference SpO~2~ statistics, stratified by sleep-state, for healthy term infants aged 2 weeks--2 years, using a current generation pulse-oximeter.

-   Cumulative frequency reference-curves provide an intuitive visual tool for rapidly evaluating whether an individual\'s SpO~2~ distribution is within a healthy range.

-   Cumulative frequency plots complement summary statistics and visual inspection of raw data in the clinical interpretation of nocturnal SpO~2~ recordings.

Introduction {#s1}
============

Modern pulse-oximeters non-invasively measure and record high temporal resolution arterial blood haemoglobin oxygen saturations (SpO~2~), making them a valuable clinical tool in a range of paediatric clinical applications. Published reference ranges have documented the normal ranges of summary measurements such as baseline SpO~2~, mean SpO~2~ and median SpO~2~ values,[@R1] with more recent studies expanding reference statistics to include ranges, nadirs, 5th and 10th percentiles of SpO~2~ distributions and time below specific SpO~2~ levels.[@R10] [@R11] However, many of these studies used devices which are no longer available in clinical practice or present selected parameters specific to particular models and averaging time settings. Furthermore, with modern oximeters capable of recording individual data points for extended periods, it is highly desirable to develop normative measurements which quantify the overall SpO~2~ distribution. This would be of particular value in the titration of supplemental oxygen requirements in infants with chronic neonatal lung disease[@R12] and screening for obstructive sleep apnoea.[@R16]

One method of presenting SpO~2~ data in a graphical, and therefore perhaps more readily interpretable manner, is the SpO~2~ cumulative frequency (CF) curve. These are produced by some commercial oximetry software, and reference values for healthy preterm infants have been presented by Harigopal *et al*[@R17] and Ng *et al*.[@R18] In this approach, the SpO~2~ CF curve was generated for each infant by calculating the proportion of the recording spent at or below each discrete SpO~2~ saturation level. CF reference-curves were then generated by calculating the 5th and 50th centiles at each SpO~2~ value for the study population. Thus, analogous to using a growth chart, by plotting the SpO~2~ CF curve for a subject of interest over the reference-curves, it can be easily observed whether the infant\'s SpO~2~ profile falls within the range expected for a healthy infant. This study thus aimed to present reference ranges for SpO~2~ summary statistics and CF reference-curves for healthy term infants from the neonatal period to 2 years of age. The impact of manual artefact removal and sleep-state stratification on CF reference-curves and summary statistics are also investigated.

Methods {#s2}
=======

Subjects and procedures {#s2a}
-----------------------

Complete details of the protocol have been described elsewhere.[@R19] Recruitment was from antenatal clinics during the third trimester of an uneventful singleton pregnancy, with 34 healthy Caucasian infants (16 girls) enrolled following birth. The intention of the initial study design was to collect normative data on various cardiorespiratory parameters, including oxygen saturation. The sample size was selected to ensure statistical power to detect maturational changes in key summary variables such as number of SpO~2~ desaturation events, while being a feasible number in which detailed sleep studies could be performed. Infants were eligible if they were: born by normal vaginal delivery or planned caesarean section at term (38--42 weeks) with normal birth weight (10th--90th percentile),[@R23] Apgar score \>7 at 5 min and were from a non-smoking household. Exclusion criteria included congenital or anatomical abnormality; sudden infant death syndrome sibling; supplemental oxygen requirement \>5 min following delivery; or a strong maternal family history of atopy.

This prospective cohort was studied with full overnight polysomnogram within the Queensland Paediatric Sleep Service at the Mater Children\'s Hospital in the neonatal period (day 5--20) and then at 3, 6, 12 and 24 months of age. Scheduled studies were conducted if the infant was well and free of inter-current illness (on physician examination). In the event of a viral respiratory illness, studies were rescheduled to at least 2 weeks after clinical resolution of the illness. A polysomnographic sleep-study was conducted using an EMBLA acquisition system (Embla N7000 system, Natus Medical Inc) and Somnologica software (Somnologica V.3.3.2 Build 1559). As part of this montage, arterial oxygen saturation was measured using a Masimo Radical (software-build 4.1, Masimo Corporation, Irvine, California, USA) pulse-oximeter with 2 s averaging and 1 Hz temporal resolution. All procedures were completed between March 2006 and July 2009, and were compliant with the Thoracic Society of Australia and New Zealand recommendations for paediatric sleep laboratories.[@R24]

Each study was manually scored by a trained, experienced scorer, with sleep-staging conducted using Anders criteria at the neonatal study[@R25] and the AASM manual for scoring sleep for infants aged 3 months and over,[@R26] as recommended by Grigg-Damberger *et al.*[@R27] This study was approved by the Mater Health Services Human Research Ethics Committee (Number 952C).

Data analysis {#s2b}
-------------

The nocturnal SpO~2~ recording for each infant, at each of the study ages, was exported from Somnologica into the European Data Format (.edf) and then imported into MATLAB (Mathworks, Natick, Massachusetts, USA) for further analysis. To account for small analogue acquisition calibration errors (\<0.5%) when digitally sampled at the polysomnogram system, SpO~2~ values were rounded to the nearest integer percentage value. The Masimo Radical oximeter has sophisticated artefact detection algorithms which mark artefactual periods by setting SpO~2~=0% and, consequently, samples of data less than 25% after rounding were removed from further analysis.

The SpO~2~ cumulative distribution function (CDF) describes the proportion of the recording spent at or below each integer SpO~2~ value, that is, for a recording of SpO~2~ samples S, and integer SpO~2~ values (x):

For each infant, at each of the five study points, a CF curve was generated using the method described by Harigopal *et al*.[@R17] Reference CF reference-curves were then generated by identifying the minimum, 25th percentile, median, 75th percentile and maximum value across the study population at each discrete SpO~2~ value to generate CF reference-curves representing the expected range of values for healthy infants at the specified age. In addition, the mean, median, 5th and 10th percentiles of SpO~2~ values (SAT5 and SAT10) were calculated for each study.

Secondary analysis included the stratification of results according to the sleep-states of wake, non-rapid eye movement (REM) and REM (wake, quiet sleep and active sleep for infants at 2 weeks);[@R27] the manual identification and removal of movement artefacts in the SpO~2~ channel (defined as changes in SpO~2~ corresponding to movement noted on video recording) which were not automatically detected; and comparison of CF reference-curves to those previously presented for healthy preterm children.[@R17] Wilcoxon-Sign-Rank tests were used to compare summary statistics in sleep-state, age and artefact rejection comparisons. p Value\<0.01 was considered statistically significant. In the event of a missing study for an infant at a particular age, that infant was excluded from statistical tests in relevant age comparisons.

Results {#s3}
=======

Of the 34 children enrolled, 31, 25, 27, 26 and 20 participants completed studies at 2 weeks, 3, 6, 12 and 24 months, respectively (see [online data supplement](http://adc.bmj.com/lookup/suppl/doi:10.1136/archdischild-2013-305708/-/DC1) 1.1, including figure S1). One study at 2 weeks had less than 60 min of artefact-free SpO~2~ data and was removed from analysis. Summary statistics of the SpO~2~ profiles calculated without manual artefact rejection for the infant population are presented in [table 1](#ARCHDISCHILD2013305708TB1){ref-type="table"}. As expected, mean duration and percentage of study time of REM decreased with maturation, while non-REM percentage of study time increased. SAT5 was lower during wake than non-REM and REM at 2 weeks and 3 months (p\<0.01) and SAT10 for the same comparison at 3 months (p\<0.01). There was an increase in median values of SAT5 and SAT10 between 2 weeks and 3 months of age for pooled non-REM and REM stratifications (p\<0.01). SAT5 and SAT10 increased during wake between 3 and 6 months (p\<0.01). The Masimo Radical pulse-oximeter was generally effective in identifying artefact (82.5%, 66.3%, 80.1%, 93.3% and 90.0% of total manually scored artefacts in infants at 2 weeks, 3, 6, 12 and 24 months, respectively). Complete summary statistics for analysis with manual artefact rejection are presented in the [online data supplement](http://adc.bmj.com/lookup/suppl/doi:10.1136/archdischild-2013-305708/-/DC1) 1.2. Analysis with manual artefact rejection did not change the population median by \>2% for any summary statistics for pooled sleep-states or in REM or non-REM, but during wake did result in a statistically significant increase of median SAT5 at 2 weeks, 3 and 12 months (p\<0.01) and a notable increase in the lower bound of the range for SAT5 and SAT10 (up to 23%).

###### 

Participant characteristics and SpO~2~ summary statistics calculated without manual artefact removal

  Summary statistic               All      non-REM/QS     REM/AS   Wake                                       
  ------------------------------- -------- -------------- -------- ------------- ------- ------------ ------- ------------
  2 weeks (N=30, 13 female)                                                                                   
   Age (days)                     14±3                                                                        
   Duration (min)                 549.6     (396--1024)   153.9     (114--544)   203.8    (93--270)   156.0    (38--357)
   Artefact-free duration (min)   503.0     (343--635)    151.2     (113--220)   193.9    (93--266)   117.6    (15--231)
   SAT5 (%Hb)                     95.0      (88--97)      96.0      (85--98)     95.0     (88--97)    92.0     (73--99)
   SAT10 (%Hb)                    96.0      (92--98)      97.0      (93--98)     96.0     (92--98)    96.0     (77--99)
   Median SpO~2~ (%Hb)            98.0      (95--100)     98.0      (95--100)    97.5     (95--100)   98.0     (96--100)
   Mean SpO~2~ (%Hb)              97.6      (95--99)      97.9      (95--99)     97.2     (95--99)    97.6     (93--100)
  3 months (N=25, 10 female)                                                                                  
  Age (days)                      97±9                                                                        
   Duration (min)                 534.5     (411--660)    249.5     (151--327)   189.5    (86--302)   75.5     (8--313)
   Artefact-free duration (min)   492.9     (391--621)    249.5     (149--327)   189.5    (73--302)   60.6     (8--169)
   SAT5 (%Hb)                     97.0      (90--99)      98.0      (94--99)     97.0     (93--99)    85.0     (68--99)
   SAT10 (%Hb)                    98.0      (95--99)      98.0      (95--100)    98.0     (94--99)    91.0     (76--100)
   Median SpO~2~ (%Hb)            99.0      (97--100)     99.0      (97--100)    99.0     (97--100)   99.0     (97--100)
   Mean SpO~2~ (%Hb)              98.5      (97--100)     98.7      (97--100)    98.9     (97--100)   97.3     (92--100)
  6 months (N=27, 10 female)                                                                                  
   Age (days)                     198±6                                                                       
   Duration (min)                 498.6     (367--680)    270.6     (160--421)   147.0    (88--229)   91.5     (20--214)
   Artefact-free duration (min)   462.5     (351--654)    262.0     (160--397)   140.0    (83--227)   66.7     (14--179)
   SAT5 (%Hb)                     97.0      (95--98)      97.0      (95--99)     97.0     (95--99)    96.0     (83--98)
   SAT10 (%Hb)                    97.0      (96--99)      98.0      (96--99)     98.0     (96--99)    97.0     (86--100)
   Median SpO~2~ (%Hb)            98.0      (97--100)     98.0      (97--100)    99.0     (97--100)   99.0     (98--100)
   Mean SpO~2~ (%Hb)              98.3      (97--100)     98.3      (97--100)    98.5     (97--100)   98.2     (96--99)
  12 months (N=26, 10 female)                                                                                 
   Age (days)                     371±14                                                                      
   Duration (min)                 499.0     (259--744)    272.3     (131--532)   128.3    (47--216)   72.0     (3--251)
   Artefact-free duration (min)   442.8     (205--612)    267.1     (119--355)   121.9    (47--216)   43.4     (3--132)
   SAT5 (%Hb)                     97.0      (89--99)      97.0      (95--99)     97.0     (83--99)    95.5     (69--99)
   SAT10 (%Hb)                    98.0      (95--99)      98.0      (95--99)     98.0     (94--99)    97.0     (75--99)
   Median SpO~2~ (%Hb)            99.0      (96--100)     98.5      (96--100)    99.0     (96--100)   99.0     (97--100)
   Mean SpO~2~ (%Hb)              98.4      (96--100)     98.4      (96--100)    98.5     (96--100)   98.2     (95--100)
  24 months (N=20, 5 female)                                                                                  
   Age (days)                     725±8                                                                       
   Duration (min)                 486.3     (323--658)    337.8     (240--512)   112.8    (41--188)   37.5     (0--155)
   Artefact-free duration (min)   481.5     (220--582)    306.7     (181--385)   103.9    (38--188)   28.9     (0--138)
   SAT5 (%Hb)                     97.5      (96--99)      98.0      (96--99)     98.0     (95--99)    97.0     (73--98)
   SAT10 (%Hb)                    98.0      (96--99)      98.0      (96--100)    98.0     (96--99)    97.0     (75--100)
   Median SpO~2~ (%Hb)            99.0      (97--100)     99.0      (97--100)    99.0     (97--100)   99.0     (97--100)
   Mean SpO~2~ (%Hb)              98.7      (97--100)     98.7      (97--100)    98.8     (97--100)   97.9     (94--100)

All summary statistics are calculated from SpO~2~ data without manual artefact removal. Data are presented for the entire recording (All), and stratified according to sleep-states non-REM, REM and wake for children at 3 months and older; and quiet sleep (QS), active sleep (AS) and wake for children at the neonatal study. SAT5, 5th percentile SpO~2~ value; SAT10, 10th percentile SpO~2~ value. Values are presented as median (range) or mean±SD. REM, rapid eye movement.

[Figure 1](#ARCHDISCHILD2013305708F1){ref-type="fig"} shows the population minimum, 25th, 50th and 75th percentiles and maximum SpO~2~ CF reference-curves generated for the study population at each of 2 weeks, 3, 6, 12 and 24 months of age. Plots are shown for the full nocturnal recording without manual artefact removal. The CF reference-curves shift right by 1% between 2 weeks and 3 months, where they remain stable up to 24 months. The same CF reference-curves overlaid with reference-curves generated using manual artefact removal are presented in [figure 2](#ARCHDISCHILD2013305708F2){ref-type="fig"}. There is no qualitative change to median or minimum population curves, but the maximum curve shows a reduced percentage of the night spent below 94% saturation. Tabulated data for these SpO~2~ CDF nomograms and those generated with sleep-state stratifications are presented in [online data supplement](http://adc.bmj.com/lookup/suppl/doi:10.1136/archdischild-2013-305708/-/DC1) 1.3, while commonly used summary statistics derived from these (percentage of night with SpO~2~ below 92% and 95%) are tabulated in [online data supplement](http://adc.bmj.com/lookup/suppl/doi:10.1136/archdischild-2013-305708/-/DC1) 1.4.

![Cumulative frequency (CF) reference-curves of SpO~2~ profiles for a population of healthy term infants aged 2 weeks, 3, 6, 12 and 24 months. CF reference-curves are derived from the nocturnal SpO~2~ recordings of 30, 25, 27, 26 and 20 infants at 2 weeks, 3, 6, 12 and 24 months of age, respectively, in a longitudinal follow-up study. Results are presented for the whole nocturnal recording, using CF plots calculated from oximetry data without manual artefact removal. The CF plot for an individual shows the percentage of a recording spent at, or below a particular SpO~2~ value, while the CF reference-curve shows the range of percentage time spent below a particular SpO~2~ value in the healthy term population. For example, it may be seen that in healthy infants at 2 weeks of age, between 0% and 60% of a recording may be spent with an SpO~2~ of 95% or less. Notably, the CF reference-curves shift right by 1%--2% between 2 weeks and 3 months, where they remain stable up to 24 months.](archdischild-2013-305708f01){#ARCHDISCHILD2013305708F1}

![SpO~2~ cumulative frequency (CF) reference-curves for healthy infants aged 2 weeks--24 months, generated with and without manual artefact removal. CF reference-curves are shown for SpO~2~ data from the whole nocturnal recording. At SpO~2~ values greater than 95%, there is no discernible deviation between nomogram curves generated with and without manual artefact removal. At lower Spo~2~ values, the maximum curve for data without manual artefact removal remains higher than the respective nomogram curve with manual artefact removal, indicating that artefact manually removed tends to be at lower SpO~2~ values. Max (Man Artfct Remvl), population maximum reference-curve generated with manual artefact removal; Med (Man Artfct Remvl), population median reference-curve generated with manual artefact removal; Min (Man Artfct Remvl), population minimum reference-curve generated with manual artefact removal.](archdischild-2013-305708f02){#ARCHDISCHILD2013305708F2}

[Figure 3](#ARCHDISCHILD2013305708F3){ref-type="fig"} compares the CF reference-curves presented in [figure 1](#ARCHDISCHILD2013305708F1){ref-type="fig"} with those presented in literature for healthy preterm infants at the same corrected age of 2 weeks post-term.[@R17] The CF reference-curves for the preterm infant group are shifted to the left relative to the healthy infant group (median curve shifted approximately 3%--4% SpO~2~).

![SpO~2~ cumulative frequency (CF) reference-curves for healthy term infants and healthy preterm infants. CF reference-curves for healthy infants at 2 weeks, overlaid with the reference-curves presented by Harigopal *et al*[@R17] for healthy preterm infants (median gestational age at birth of 33 weeks; median age at study of 2 weeks). The reference-curves for the preterm infant group are shifted to the left relative to the term infant group (median curve shifted approximately 3%--4% SpO~2~). Physiological differences in the oxy-haemoglobin dissociation curve, use of different pulse-oximeter models and the extent of manual artefact removal may account for these differences.](archdischild-2013-305708f03){#ARCHDISCHILD2013305708F3}

Discussion {#s4}
==========

The objective of this study was to present reference ranges of nocturnal SpO~2~ recordings from a prospective cohort of healthy term infants at 2 weeks, 3, 6, 12 and 24 months of age using both conventional summary statistics and CF reference-curves. To our knowledge, this is the first study to present reference ranges recorded using a Masimo Radical pulse-oximeter with 2 s averaging in a prospective cohort of healthy term infants from 2 weeks to 24 months. This study was conducted in a sleep-laboratory and, as such, secondary analyses investigated the impact of sleep-state and manual artefact identification on reference ranges.

The SpO~2~ summary statistics presented for entire nocturnal recordings are generally consistent with the literature despite the recognised variations in recorded SpO~2~ values between different oximeter makes and models.[@R30] In particular, the population range of mean and median nocturnal SpO~2~ values was between 95% and 100% over the first 2 years.[@R2] [@R5] [@R6] [@R31] [@R32] Median SAT5 was 95% at 2 weeks which supports existing studies that show healthy term neonates have nocturnal SAT5 values as low as 95%[@R10] and these lower end SpO~2~ values tend to increase and stabilise over the first few months of life.[@R31] These results provide important normative data using a current generation high temporal resolution pulse-oximeter. While this is the first study to present CF reference-curves for healthy term infants, these curves have previously been presented in literature for a cohort of healthy preterm infants.[@R17] It was noted in the results that there was a left shift of 3%--4% in the median curve for preterm infants indicating that SpO~2~ values are lower in the preterm group. Physiological differences in the oxy-haemoglobin dissociation curve, use of different pulse-oximeter models[@R30] and the extent of artefact removal may account for these differences.

Sleep-state stratification confirmed earlier work that there is no clinically significant difference (\>2%) in summary measures of SpO~2~ between REM and non-REM sleep-states,[@R1] and this was reflected in CF reference-curves (see [online data supplement](http://adc.bmj.com/lookup/suppl/doi:10.1136/archdischild-2013-305708/-/DC1) 1.3). Although we found that SAT5 and SAT10 were lower during wake than sleep at 2 weeks and 3 months, this may be related to the additional likelihood of movement artefact during wake which was not detected by the automatic algorithm. While results indicated that Masimo Radical\'s artefact identification was good, manual artefact removal during wakefulness resulted in an increase in summary statistics (particularly SAT5) and deviation in CDF\'s (observed as lower percentage of time spent below 90%). No difference was found in either SpO~2~ summary statistics or SpO~2~ CDF nomograms for pooled data, REM or non-REM stratifications following manual artefact rejection. These results suggest that clinical utility would not be limited by the inability to classify sleep-stage, although there would be benefit to manually excluding obvious movement artefacts during wake from analysis (see [online data supplement](http://adc.bmj.com/lookup/suppl/doi:10.1136/archdischild-2013-305708/-/DC1) 1.5 for further discussion).

The CF reference-curve has previously been proposed as a useful clinical tool for interpreting extended SpO~2~ recordings due to its ability to present information about the SpO~2~ distribution in an intuitive graphical manner.[@R17] [@R18] Indeed, SpO~2~ CF curves for individuals can be produced with some commercial oximetry and polysomnogram software, and may be readily generated using standard spreadsheet software (see online data supplement 2 provides a brief tutorial). Yet, to date, CF reference-curves for healthy term infants have been lacking. This study thus provides important reference data to allow this method to be translated into wider clinical practice. To illustrate the potential clinical utility of CF reference-curves, [figure 4](#ARCHDISCHILD2013305708F4){ref-type="fig"} displays the CF curves for an infant with chronic neonatal lung disease at 3 months gestational corrected age during an oxygen titration study superimposed on the CF reference-curves for infants at 3 months. It can be observed that when the infant is in room air, the CF is shifted to the left of the normative range indicating that SpO~2~ values are lower than may be expected in healthy infants. However, when the same infant is placed in supplemental oxygen at 0.25 L/min, the CF curve is within the healthy range, indicating normal SpO~2~ distribution. The CF curve alone does not discriminate between a large number of short desaturations or a smaller number of longer desaturations and, as such, best clinical utility would be achieved by using CF curves to complement summary statistics and visual inspection of large time-scale trend graphs. As with all diagnostic tests, results need to be interpreted in the wider clinical context.

![Effect of supplemental oxygen on an infant with chronic neonatal lung disease at 3 months corrected age during an oxygen titration study. Cumulative frequency (CF) plots for an infant with chronic neonatal lung disease at 3 months gestational corrected age, plotted over the SpO~2~ CF reference-curves for healthy infants at 3 months. It can be observed that when the infant is in room air, the CF plot is shifted to the left of the normative range indicating that SpO~2~ values are lower than may be expected in healthy infants. However, when treated with 0.25 L/min of supplemental oxygen, the CF plot is within the healthy range indicating normal SpO~2~ distribution.](archdischild-2013-305708f04){#ARCHDISCHILD2013305708F4}

There are a number of limitations in this study. First, participants were continuously supervised by an experienced sleep technologist to ensure that all sensors remained correctly attached, likely resulting in fewer artefacts than expected in a general clinical environment. While this provides the scientific advantage of improved data quality, it may limit generalisability to other clinical environments. Second, generalisability is also potentially restricted to the pulse-oximeter used in this study. However, it is a commercially available model and is commonly used in hospital settings. Finally, this was a resource-intensive sleep-laboratory based prospective cohort follow-up study, and consequently results may also be limited by a relatively small sample size. This may have particular impact on maximum and minimum CF reference-curves, and these should be interpreted as the maximum and minimum in this sample, rather than the expected limits for the wider population. Future work should expand these results by studying a larger sample in a more generalised clinical environment.

In conclusion, this paper presents reference ranges for healthy term infants aged from 2 weeks to 24 months of nocturnal SpO~2~ recordings using a Masimo Radical pulse-oximeter with 2 s averaging. The SpO~2~ CF reference-curves provide an intuitive visual tool for evaluating whether an individual infant\'s nocturnal SpO~2~ distribution falls within the range of healthy age-matched infants. This reference range is potentially applicable to extended oximetry studies conducted in a range of generalised care settings and may be a useful tool in monitoring and setting appropriate supplemental oxygen levels for infants with respiratory and other diseases.
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